<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141424">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151383</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2208</org_study_id>
    <secondary_id>2013-002847-28</secondary_id>
    <nct_id>NCT02151383</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics &amp; Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure</brief_title>
  <official_title>Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to &lt;18 Years of Age, Hospitalized With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: German Federal Institute for Drugs and Medical Devices (BfArM)</authority>
    <authority>Switzerland: Swiss Agency for Therapeutic products (Swissmedic)</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of an
      intravenous infusion of serelaxin on top of standard of care therapy, in pediatric patients
      with acute heart failure (AHF)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients reported with adverse events, serious adverse events and death</measure>
    <time_frame>through 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse events (including confirmed systolic blood pressure decreases and worsening heart failure), serious adverse events and death will be analyzed in order to evaluate the safety and tolerability of intravenous serelaxin in AHF patients. Adverse events will be assessed by signs/symptoms, clinical laboratory and electrocardiographs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Css (steady state concentration)</measure>
    <time_frame>at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: CL (clearance)</measure>
    <time_frame>at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of arterial BP</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of central venous pressure (CVP)</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of left atrial pressure (LAP)</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of pulmonary artery pressure (PAP- systolic and diastolic)</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of central venous and arterial oxygen saturation</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of urine output</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of blood lactate levels</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Serelaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serelaxin will be administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <description>Serelaxin will be administered intravenously for up to 48 hours.</description>
    <arm_group_label>Serelaxin</arm_group_label>
    <other_name>RLX030</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Body weight ≥2.5 kg to ≤120 kg

          -  Hospitalized in an intensive care unit or step-down unit with the following:

          -  - Signs and symptoms of acute heart failure of any etiology

          -  - Stable dose of vasoactive and/or inotropic drugs

          -  - For non-surgical patients echocardiographic evidence of reduced ventricular
             function (ejection fraction &lt;50% or fractional shortening &lt;28%)

          -  Systolic blood pressure (SBP) ≥25th percentile SBP for age and gender.

        EXCLUSION CRITERIA:

          -  Moderate to severe left ventricular outflow tract, mitral stenosis, or aortic arch
             obstruction

          -  Single ventricle physiology

          -  Fixed pulmonary hypertension

          -  Blood lactate levels &gt;5 mmol/L at screening

          -  Birth &lt; 36 weeks post-conceptual age (for patients &lt;1year old)

          -  Confirmed or clinically suspected systemic infection or severe localized infection

          -  Dyspnea or acute lung injury primarily due to non-cardiac causes

          -  Patients with severe renal impairment, those known to have significant renal disease
             and those having renal replacement therapy

          -  High use of inotropic and/or vasoactive agents at screening

          -  Electrocardiographic abnormalities

          -  Solid organ transplant recipient within 1 year of transplantation or one who presents
             with severe organ rejection

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute heart failure</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
